Fred Grossman Purchases 2,710 Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) insider Fred Grossman purchased 2,710 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average price of $7.37 per share, for a total transaction of $19,972.70. Following the purchase, the insider now directly owns 2,710 shares in the company, valued at $19,972.70. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Coya Therapeutics Stock Performance

COYA stock traded down $0.08 during trading on Tuesday, reaching $7.25. 75,269 shares of the company traded hands, compared to its average volume of 71,656. The company has a market capitalization of $121.13 million, a price-to-earnings ratio of -11.15 and a beta of 0.46. Coya Therapeutics, Inc. has a 12 month low of $4.75 and a 12 month high of $10.69. The business has a 50 day simple moving average of $7.05 and a 200 day simple moving average of $7.02.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15. As a group, research analysts forecast that Coya Therapeutics, Inc. will post -1.27 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GHP Investment Advisors Inc. purchased a new stake in shares of Coya Therapeutics during the 3rd quarter worth $169,000. Renaissance Technologies LLC purchased a new position in shares of Coya Therapeutics in the second quarter valued at $101,000. Gilbert & Cook Inc. purchased a new position in Coya Therapeutics during the second quarter worth $61,000. Finally, Vanguard Group Inc. grew its stake in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after acquiring an additional 750,338 shares during the period. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on COYA. Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.